A holistic approach to improving drug and device safety

The mission of pharmacovigilance (PV) is to “detect, assess, understand and prevent adverse events (AEs).”1 PV continues to grow more complex, partly due to a continuing rise in AEs, additional channels to monitor and increasingly stringent regulatory requirements. With timeliness and quality of safety operations as critical as ever, cognitive computing offers new capabilities to add speed, scale and consistency to the entire pharmacovigilance process from AE detection, evaluation and reporting, to signal detection and assessment.

1 World Health Organization definition of pharmacovigilance.

Featured findings

Over half of life sciences executives surveyed said they plan to adopt cognitive computing for pharmacovigilance within the next 3 years
Real-time safety insight from proactive surveillance could be a game-changing leap forward from today's reactive approaches.
The promise of more safety data is the insight it could yield; the potential downside is that improper analysis could yield incorrect insights and jeopardize patient well-being.

About the authors

Elenee Argentinis

Elenee Argentinis
Offering Leader, Watson for Patient Safety
IBM Watson Health

Louisa Roberts

Louisa Roberts
IBM Watson Health Life Sciences

Heather Fraser

Heather Fraser
Life Sciences and Healthcare Team Leader
IBM Institute for Business Value

Read related IBM executive reports

Prescribing a digital transformation for life sciences

Your cognitive future in life sciences

A booster shot for health and wellness

Your cognitive future in the healthcare industry

Reinventing life sciences

How emerging ecosystems fuel innovation